SG11202111012QA - Trispecific binding proteins, methods, and uses thereof - Google Patents
Trispecific binding proteins, methods, and uses thereofInfo
- Publication number
- SG11202111012QA SG11202111012QA SG11202111012QA SG11202111012QA SG11202111012QA SG 11202111012Q A SG11202111012Q A SG 11202111012QA SG 11202111012Q A SG11202111012Q A SG 11202111012QA SG 11202111012Q A SG11202111012Q A SG 11202111012QA SG 11202111012Q A SG11202111012Q A SG 11202111012QA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- binding proteins
- trispecific binding
- trispecific
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962831572P | 2019-04-09 | 2019-04-09 | |
EP19306261 | 2019-10-02 | ||
PCT/US2020/027320 WO2020210392A1 (en) | 2019-04-09 | 2020-04-08 | Trispecific binding proteins, methods, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202111012QA true SG11202111012QA (en) | 2021-11-29 |
Family
ID=72751423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202111012QA SG11202111012QA (en) | 2019-04-09 | 2020-04-08 | Trispecific binding proteins, methods, and uses thereof |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP3953388A1 (zh) |
JP (1) | JP2022527994A (zh) |
KR (1) | KR20210149141A (zh) |
CN (1) | CN113950484A (zh) |
AU (1) | AU2020272839A1 (zh) |
BR (1) | BR112021019915A2 (zh) |
CA (1) | CA3136821A1 (zh) |
CO (1) | CO2021014918A2 (zh) |
IL (1) | IL286929A (zh) |
MX (1) | MX2021012386A (zh) |
SG (1) | SG11202111012QA (zh) |
TW (1) | TW202104261A (zh) |
WO (1) | WO2020210392A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024077118A2 (en) * | 2022-10-06 | 2024-04-11 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9200061B2 (en) * | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
TWI803876B (zh) * | 2011-03-28 | 2023-06-01 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
WO2016033690A1 (en) * | 2014-09-04 | 2016-03-10 | Stemcell Technologies Inc. | Soluble antibody complexes for t cell or nk cell activation and expansion |
PE20171764A1 (es) * | 2015-01-23 | 2017-12-21 | Sanofi Sa | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123 |
WO2016205531A2 (en) * | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Anti-her2 antibodies and methods of use |
BR112018008011A2 (pt) | 2015-10-25 | 2018-10-30 | Sanofi | proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv |
BR112018070998A2 (pt) | 2016-04-13 | 2019-02-26 | Sanofi | proteínas de ligação triespecíficas e/ou trivalentes |
EP3575319A4 (en) * | 2016-12-30 | 2021-03-10 | Shanghai Sinobio Biotech Co., Ltd. | BIFUNCTIONAL MOLECULE AND USE OF IT |
CN117964758A (zh) * | 2017-10-10 | 2024-05-03 | 赛诺菲 | 抗cd38抗体及与抗cd3和抗cd28抗体的组合 |
US11530268B2 (en) * | 2018-10-09 | 2022-12-20 | Sanofi | Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection |
-
2020
- 2020-04-08 CA CA3136821A patent/CA3136821A1/en active Pending
- 2020-04-08 BR BR112021019915A patent/BR112021019915A2/pt unknown
- 2020-04-08 WO PCT/US2020/027320 patent/WO2020210392A1/en unknown
- 2020-04-08 EP EP20722422.1A patent/EP3953388A1/en active Pending
- 2020-04-08 CN CN202080041550.1A patent/CN113950484A/zh active Pending
- 2020-04-08 AU AU2020272839A patent/AU2020272839A1/en active Pending
- 2020-04-08 TW TW109111809A patent/TW202104261A/zh unknown
- 2020-04-08 KR KR1020217036094A patent/KR20210149141A/ko unknown
- 2020-04-08 MX MX2021012386A patent/MX2021012386A/es unknown
- 2020-04-08 SG SG11202111012QA patent/SG11202111012QA/en unknown
- 2020-04-08 JP JP2021559759A patent/JP2022527994A/ja active Pending
-
2021
- 2021-10-03 IL IL286929A patent/IL286929A/en unknown
- 2021-11-04 CO CONC2021/0014918A patent/CO2021014918A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022527994A (ja) | 2022-06-07 |
CO2021014918A2 (es) | 2021-11-19 |
AU2020272839A1 (en) | 2021-12-02 |
TW202104261A (zh) | 2021-02-01 |
CA3136821A1 (en) | 2020-10-15 |
CN113950484A (zh) | 2022-01-18 |
MX2021012386A (es) | 2022-01-18 |
EP3953388A1 (en) | 2022-02-16 |
KR20210149141A (ko) | 2021-12-08 |
BR112021019915A2 (pt) | 2021-12-07 |
WO2020210392A1 (en) | 2020-10-15 |
IL286929A (en) | 2021-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT3443006T (pt) | Proteínas de ligação triespecíficas e/ou trivalentes | |
IL277398A (en) | PD-L1 binding epimers and related uses thereof | |
EP3452089A4 (en) | BISPECIFIC BINDING PROTEINS AND USES THEREOF | |
IL278943A (en) | Multi-specificity binding proteins and improvements thereof | |
IL265489B (en) | Recombinant binding proteins and their uses | |
EP3655432A4 (en) | BINDING PROTEIN 1 | |
IL268755A (en) | HER2, NKG2D, and CD16 binding proteins | |
EP3613772A4 (en) | SPECIFIC BINDING MOLECULE FOR LRIG-1 PROTEIN AND ITS USE | |
IL268567A (en) | BCMA, NKG2D and CD16 binding proteins | |
EP3689893A4 (en) | IMMUNOGLOBULIN-BINDING PROTEIN AND AFFINITY CARRIERS THEREFORE | |
IL284664A (en) | Multispecific binding proteins | |
EP3515948A4 (en) | COAGULATION FACTOR BINDING PROTEINS AND USES THEREOF | |
EP3380514A4 (en) | GDF131-BINDING PROTEINS AND USES THEREOF | |
ZA202103259B (en) | Modified cas9 protein, and use thereof | |
EP3705121A4 (en) | EMOPAMIL BINDING PROTEIN BINDING AGENT AND ITS USE | |
EP3689894A4 (en) | IMMUNOGLOBULIN-BINDING PROTEIN AND AFFINITY CARRIERS THEREFORE | |
EP3882266A4 (en) | LRIG-1 PROTEIN SPECIFIC BINDING MOLECULE AND USE THEREOF | |
IL284317A (en) | FAB pseudoproteins are multispecific binding proteins | |
EP3700571A4 (en) | ALK7-BINDING PROTEINS AND USES THEREOF | |
IL304317A (en) | tgf–beta–rii binding proteins | |
IL286929A (en) | Tri-specific binding proteins, methods, and their use | |
IL289145A (en) | il1rap binding proteins | |
EP4077385A4 (en) | CXCL10-BINDING PROTEINS AND USES THEREOF | |
EP3976630A4 (en) | ACTRII-BINDING PROTEINS AND THEIR USES | |
EP3973550C0 (en) | PEPTIDE IONOGEL, COMPOSITION, METHODS AND USES THEREOF |